TABLE 2.
Detection target | Collected samples | Limit of detection (LoD) | Manufacturer | Detection principle | Diagnostic | Source |
---|---|---|---|---|---|---|
ORF1ab, E gene | individual or pooled nasal, nasopharyngeal, and oropharyngeal swab samples |
Target 1 (SARS‐CoV‐2): 25 copies/ml (95% CI: 17–58 copies/ml) Target 2 (pan‐Sarbecovirus): 32 copies/ml (95% CI: 21–73 copies/ml) |
Roche Molecular Systems, Inc. (RMS) | Real‐time RT‐PCR | Cobas SARS‐CoV‐2 | 126 |
ORF1ab and N gene | upper respiratory tract specimens | 1 copy/μl | SEASUN BIOMATERIALS, Inc. | RT‐LAMP | AQ‐TOP COVID‐19 Rapid Detection Kit PLUS | 127 |
upper respiratory and BAL specimens | 150 copies/ml | Euroimmun US, Inc. | Real‐time RT‐PCR | EURORealTime SARS‐Cov‐2 | 128 | |
N gene, RNase P gene | nasopharyngeal, anterior nasal, mid‐turbinate, oropharyngeal swab specimens, nasopharyngeal wash/aspirate, and nasal aspirate specimens |
640 GC/ml (Determination of SARS‐CoV‐2 heat‐inactivated virus) 40 GE/ml (Detection of quantified genomic viral RNA from SARS‐CoV‐2) |
Becton, Dickinson and Company (BD) | Real‐time RT‐PCR | BD SARS‐CoV‐2 Reagents for BD MAX System | 129 |
nasopharyngeal swab, oropharyngeal swab, mid‐turbinate nasal swab, and anterior nasal swab specimens | 0.125 copies/μl | Fluidigm Corporation | Real‐time RT‐PCR | Advanta Dx COVID‐19 EASE assay | 130 | |
upper respiratory specimens | 20 copies/μl | Mammoth Biosciences, Inc. | RT‐LAMP, CRISPR/Cas12 | SARS‐CoV‐2 DETECTR Reagent Kit | 131 | |
anterior nares specimens | 250 copies/swab | LGC, Biosearch Technologies | End‐Point RT‐PCR | Biosearch Technologies SARS‐CoV‐2 ultra‐high‐throughput End‐Point RT‐PCR Test | 132 | |
upper respiratory specimens | 1.2 copies/μl | Exact Sciences Laboratories | Real‐time RT‐PCR | SARS‐CoV‐2 (N gene detection) Test | 133 | |
anterior nasal swab specimens | 6.25 copies/μl | Premier Medical Laboratory Services | Real‐time RT‐PCR | PMLS SARS‐CoV‐2 Assay | 134 | |
nasopharyngeal and oropharyngeal swab specimens | 1 copy/μl | Avellino Lab USA, Inc. | Real‐time RT‐PCR | AvellinoCoV2 test | 135 | |
OFR1ab, N gene, RNase P gene | nasopharyngeal swabs, and anterior or mid‐turbinate nasal swabs |
Nasopharyngeal swab: 75 GCE/ml of sample Anterior nasal swab: 75 GCE/ml of sample |
Thermo Fisher Scientific Inc. | Real‐time RT‐PCR | TaqPath COVID‐19 RNase P Combo Kit 2.0 | 136 |
upper respiratory tract specimens and bronchoalveolar lavage specimens |
ORF1ab target: 6.75 cp/μl VTM N target: 1.35 cp/μl VTM |
Sherlock BioSciences, Inc. | Sherlock,RT‐LAMP, CRISPR | Sherlock CRISPR SARS‐CoV‐2 Kit | 137 | |
N and E gene | nasopharyngeal (NP), oropharyngeal (OP), mid‐turbinate (MT), and anterior nares (nasal) swabs | 75 copies/μl | MobileDetect Bio Inc. | RT‐LAMP | MobileDetect Bio BCC19 (MD‐Bio BCC19) Test Kit | 138 |
upper respiratory specimens | 0.0200 PFU/ml | Cepheid | Real‐time RT‐PCR | Xpert Xpress SARS‐CoV‐2 test | 139 | |
saliva specimens | 6400 GE/ml | MicroGEM U.S., Inc. | Real‐time RT‐PCR | MicroGEM Sal6830 SARS‐CoV‐2 Saliva Test | 140 | |
N gene | upper respiratory tract specimens | 20 copies/μl | UCSF Health Clinical Laboratories, UCSF Clinical Labs at China Basin | RT‐LAMP, CRISPR/Cas12 | SARS‐CoV‐2 RNA DETECTR Assay | 141 |
nasopharyngeal, anterior nasal, mid‐turbinate nasal, or oropharyngeal swab specimens | 100 copies/ml (nasopharyngeal matrix) | Mammoth Biosciences, Inc | RT‐LAMP, CRISPR | DETECTR BOOST SARS‐CoV‐2 Reagent Kit | 142 | |
ORF1ab | anterior nasal swab samples | 800 copies/ml | Detect, Inc. | LAMP, Lateral Flow Strips | Detect Covid‐19 Test | 143 |
RdRP, E, and N genes | nasopharyngeal (NP), oropharyngeal (OP), bronchoalveolar lavage (BAL) specimens | 140 copies/ml | PlexBio Co., Ltd. | RT‐PCR | IntelliPlex SARS‐CoV‐2 Detection Kit | 144 |
N, ORF1ab, S gene, RNase P RNA (and DNA) | anterior nasal swab specimens | 1 copy/μl | UCSD BCG EXCITE Lab | Real‐time RT‐PCR | UCSD EXCITE COVID‐19 EL Test | 145 |